Sanofi reveals promising data for FDA-delayed diabetes drug
pharmafile | September 14, 2016 | News story | Research and Development, Sales and Marketing | FDA, Lantus, Sanofi, iglarlixi
Sanofi has announced new Phase III data for its IGlarLixi combination drug for the treatment of diabetes, showing it could be more effective than its Lantus blockbuster.
The FDA delayed its review of the drug in August, citing a lack of adequate data.
IGlarLixi combines the active ingredients in Lantus (insulin glargine) with Sanofi’s GLP-1 agonist Lyxumia (lixisenatide). According to the new findings, the combination drug proved more effective in controlling mealtime blood glucose than Lantus, helping more type 2 diabetes patients reach post-prandial glucose targets.
“Controlling mealtime blood sugar is an important element of maintaining overall blood sugar control, which plays a role in helping patients treat their diabetes,” commented Josep Vidal of the Hospital Clinic of Barcelona, who presented the results at the European Association for the Study of Diabetes (EASD) meeting in Munich.
Prior results from the LixiLan-L trial have shown that the combination is more effective than Lantus in controlling haemoglobin A1c levels, a biomarker for glucose control over time.
Matt Fellows
Related Content
Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia
Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib …
FDA approves ImmunityBio’s Anktiva bladder cancer treatment
ImmunityBio has announced that the US Food and Drug Administration (FDA) has approved Anktiva (N-803, …
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …